test (8) . The MIC was taken as the lowest dilution of antimicrobial agent that showed no turbidity after overnight incubation. The MBCs were determined in a similar manner by using an initial inoculum of 1.5 x 106 CFU and by culturing onto nutrient agar 0.01 ml of the broth from wells which showed no turbidity. The MBC was defined as the lowest dilution of antibiotic that completely inhibited growth on nutrient agar after a further overnight incubation. Table 1 summarizes the inhibitory and bactericidal activities of the 12 antibiotics against the 100 isolates of P. pseudomallei. Imipenem showed the highest activity in vitro with an MIC and MBC for 90% of strains of 1 and 2 jig/ml, respectively. The P-lactamase-resistant ureidopenicillins (azlocillin and piperacillin), the cephems, and carumonam were also highly potent in vitro against test strains of P. pseudomallei, while aztreonam was found to be variable in its activity, with MICs and MBCs ranging from 2 to 16 and 4 to 32 ,ug/ml, respectively. In contrast to the newer ,B-lactam drugs under study, the quinolones, ciprofloxacin and norfloxacin, were considerably less active against P. pseudomallei, with MICs and MBCs ranging from 0.5 to 32 and 1 to 32 ,ug/ml, respectively.
The results of this study are similar to those obtained in previous studies with the agar dilution technique and strains isolated from various regions of Asia (4, 5) . Although the methods varied, these studies suggest that there is little difference in patterns of susceptibility to the newer antibiotics among P. pseudomallei strains from different geographic areas.
Generally, the difference in MICs and MBCs was a twofold dilution for both the P-lactam antibiotics and the quinolones. Azlocillin, piperacillin, cefotaxime, ceftazidime, ceftriaxone, imipenem, and carumonam were bactericidal in vitro against all 100 strains of P. pseudomallei at concentrations readily achievable in the sera of humans. On the basis of their in vitro activities alone, any one of these drugs would be suitable for the empirical or specific treatment of melioidosis; and these antimicrobial agents are therefore candidates for clinical trials of serious infections with P. pseudomallei, particularly in view of the success, in isolated cases, of the broad-spectrum cephalosporins in controlling P. pseudomallei infection (10, 11) . Which drug to use would probably depend more on cost, availability, and pharmacokinetic properties relevant to the clinical situation rather than antimicrobial activity per se.
It was not surprising that all strains of P. pseudomallei were found to be resistant to amoxicillin and ticarcillin, since ANTIMICROB. AGENTS CHEMOTHER. P. pseudomallei is known to be a P-lactamase-producing organism (3). When these drugs were combined with the ,-lactamase-inhibitor clavulanic acid, they were considerably active in vitro. Except for three strains which were totally resistant, amoxicillin-clavulanic acid showed inhibitory and bactericidal activities in vitro against all P. pseudomallei strains at 4 and 8 ,ug/ml, respectively. The successful therapeutic management of clinical cases of melioidosis requires a long-term, high-dose regimen which traditionally has involved the oral administration of tetracycline or one of its analogs or sulfamethoxazole-trimethoprim or both (2, 6 
